On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
https://european-biotechnology.com/wp-content/uploads/2024/04/RS1684_AdobeStock_39048791-scaled.jpeg17072560Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2023-12-05 11:13:082024-07-09 12:58:33$30m for genetic medicine advancements
https://european-biotechnology.com/wp-content/uploads/2024/04/Cradle_Team.jpg10791440Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-11-28 09:44:082024-07-09 12:55:45AI protein specialist Cradle raises US$24m in Series A financing
British and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain.
Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.
UK publishes £2bn vision for engineering biology
Latest NewsOn the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Valnevas Lyme vaccine trial completes recruitment
Latest NewsPfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Unveiling prostate cancer’s Achilles’ heel
Latest NewsResearchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.
$30m for genetic medicine advancements
Latest NewsEligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
Takeover in ADC space: Abbvie snags ImmunoGen
Latest NewsAbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.
AI protein specialist Cradle raises US$24m in Series A financing
Latest NewsGenerative AI protein engineering specialist Cradle NV, has raised US$24m in a Series A financing round led by Index Ventures w
Repairing MS-caused damage with stem cells
Latest NewsBritish and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain.
Breakthrough in COPD treatment
Latest NewsFrench Sanofi SA’s second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.
Novo Nordisk invests €2.1bn in production expansion
Latest NewsIn the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.
Quotient Therapeutics kicks-off with US$50m financing
Latest NewsFlagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.